Tony Coles

Chairman and Chief Executive Officer at Yumanity Therapeutics

Dr. Coles is a founding investor and the chairman and chief executive officer of Yumanity Therapeutics. Previously, Dr. Coles was chairman and chief executive officer of Onyx Pharmaceuticals, Inc., which was acquired by Amgen in late 2013. Under his leadership, Onyx introduced two new innovative cancer medicines to patients and established the company’s international presence outside of the U.S. Prior to joining Onyx in 2008, he was president, chief executive officer and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was senior vice president of commercial operations at Vertex Pharmaceuticals Inc., and earlier, held a number of executive positions at Bristol- Myers Squibb Company and positions of increasing responsibility at Merck & Co., Inc. Educated at Johns Hopkins University, he earned a medical degree from Duke University and a master’s degree in public health from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School. Dr. Coles currently serves on the board of directors of McKesson Corporation (NYSE: MCK) and Regeneron (NASDAQ: REGN) and is a member of the board of trustees for Johns Hopkins University and Johns Hopkins Medicine. Dr. Coles is also a member of the Council for the Smithsonian’s National Museum of African American History and Culture in Washington, D.C.; a member of the board of trustees for The Metropolitan Museum of Art in New York City; a member of the board of directors of the Council on Foreign Relations, an independent, nonpartisan membership organization, think tank, and publisher; and a member on the Harvard Medical School Advisory Board.

Alle sessies door Tony Coles

Fireside Chat

Room 205ABC, Level 2